APP V715A (German)


Pathogenicity: Alzheimer's Disease : Pathogenic
Clinical Phenotype: Alzheimer's Disease
Reference Assembly: GRCh37 (105)
Position: Chr21:27264101 T>C
dbSNP ID: rs63750868
Coding/Non-Coding: Coding
Mutation Type: Point, Missense
Codon Change: GTG to GCG
Reference Isoform: APP Isoform APP770 (770 aa)
Genomic Region: Exon 17


This mutation, near the γ-secretase cleavage site in APP, was first reported in a German pedigree. The proband was a 50-year-old woman with a family history of dementia consistent with autosomal-dominant inheritance. She demonstrated progressive cognitive impairment and fulfilled NINCDS-ADRDA criteria for probable Alzheimer's disease. The mean age of onset for the four affected members of this family was 52 years (Cruts et al., 2003).  

This mutation was also found in a female patient in Poland who met NINCDS-ADRDA criteria for probable Alzheimer's disease with significant impairment of verbal memory and decline in visuospatial functioning. Symptoms started at age 42. Family history was unavailable (Zekanowski et al., 2003).

The V715A mutation was also found in a large French study reporting 56 new families with autosomal-dominant, early onset Alzheimer’s disease. All probands met NINCDS-ADRDA criteria for probable AD and had a family history of disease (Wallon et al., 2012). The V715A mutation was detected in one individual in a family known as EXT 147, which had 10 known affected family members. Only the genotype of the proband is known, therefore segregation with disease could not be determined. Age of onset in this family ranged from 40 to 44 years of age, with a six- to 13-year disease course. The mutation was classified as definitely pathogenic according to the algorithm proposed by Guerreiro et al., 2010.


PET imaging showed hypoperfusion in the parieto-occipital region (Cruts et al., 2003).

Biological Effect

This mutation increased the Aβ42/Aβ40 ratio approximately fourfold in HEK293 cells (Cruts et al., 2003). A similar increase was also observed in primary neuronal cultures, with a decrease in Aβ40 and an increase in Aβ42 (De Jonghe et al., 2001). A study using NMR spectroscopy found that this mutation, along with V715M at the same position, altered the structure and dynamics of the transmembrane domain in APP, making it more accessible to γ-secretase for ε-cleavage, and consequently shifting production toward Aβ42 (Chen et al., 2014).


No Available Comments

Make a Comment

To make a comment you must login or register.


Paper Citations

  1. . Novel APP mutation V715A associated with presenile Alzheimer's disease in a German family. J Neurol. 2003 Nov;250(11):1374-5. PubMed.
  2. . Mutations in presenilin 1, presenilin 2 and amyloid precursor protein genes in patients with early-onset Alzheimer's disease in Poland. Exp Neurol. 2003 Dec;184(2):991-6. PubMed.
  3. . Genetic screening of Alzheimer's disease genes in Iberian and African samples yields novel mutations in presenilins and APP. Neurobiol Aging. 2010 May;31(5):725-31. Epub 2008 Jul 30 PubMed.
  4. . Pathogenic APP mutations near the gamma-secretase cleavage site differentially affect Abeta secretion and APP C-terminal fragment stability. Hum Mol Genet. 2001 Aug 1;10(16):1665-71. PubMed.
  5. . Familial Alzheimer's mutations within APPTM increase Aβ42 production by enhancing accessibility of ε-cleavage site. Nat Commun. 2014;5:3037. PubMed.

Other Citations

  1. V715M

Further Reading

Learn More

  1. Alzheimer Disease & Frontotemporal Dementia Mutation Database

Protein Diagram

Primary Papers

  1. . Novel APP mutation V715A associated with presenile Alzheimer's disease in a German family. J Neurol. 2003 Nov;250(11):1374-5. PubMed.

Other mutations at this position


Disclaimer: Alzforum does not provide medical advice. The Content is for informational, educational, research and reference purposes only and is not intended to substitute for professional medical advice, diagnosis or treatment. Always seek advice from a qualified physician or health care professional about any medical concern, and do not disregard professional medical advice because of anything you may read on Alzforum.